IRIS
RADAELLI, MARTA
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
EU - Europa 2.610
AS - Asia 2.143
NA - Nord America 1.470
SA - Sud America 526
AF - Africa 37
Continente sconosciuto - Info sul continente non disponibili 2
Totale 6.788
Salva come PNG Salva come JPEG
Nazione #
RU - Federazione Russa 1.456
US - Stati Uniti d'America 1.404
SG - Singapore 845
CN - Cina 680
BR - Brasile 453
SE - Svezia 308
RO - Romania 266
HK - Hong Kong 224
VN - Vietnam 201
IT - Italia 117
FR - Francia 114
DE - Germania 109
GB - Regno Unito 78
IN - India 42
FI - Finlandia 35
AR - Argentina 29
NL - Olanda 29
CA - Canada 28
MX - Messico 26
JP - Giappone 23
PL - Polonia 22
ZA - Sudafrica 21
BD - Bangladesh 18
TR - Turchia 18
IE - Irlanda 17
IR - Iran 17
EC - Ecuador 16
ID - Indonesia 16
ES - Italia 12
IQ - Iraq 12
AT - Austria 10
CO - Colombia 8
UA - Ucraina 8
SA - Arabia Saudita 7
UZ - Uzbekistan 7
PK - Pakistan 6
CH - Svizzera 5
CL - Cile 5
JO - Giordania 5
LT - Lituania 5
PY - Paraguay 5
PH - Filippine 4
TN - Tunisia 4
VE - Venezuela 4
AE - Emirati Arabi Uniti 3
AL - Albania 3
CZ - Repubblica Ceca 3
DO - Repubblica Dominicana 3
EG - Egitto 3
MD - Moldavia 3
PE - Perù 3
UY - Uruguay 3
EU - Europa 2
HU - Ungheria 2
IL - Israele 2
KE - Kenya 2
MA - Marocco 2
MY - Malesia 2
NI - Nicaragua 2
NO - Norvegia 2
NP - Nepal 2
PA - Panama 2
PT - Portogallo 2
AZ - Azerbaigian 1
BB - Barbados 1
BE - Belgio 1
BF - Burkina Faso 1
CI - Costa d'Avorio 1
CY - Cipro 1
ET - Etiopia 1
GA - Gabon 1
GD - Grenada 1
GR - Grecia 1
JM - Giamaica 1
KG - Kirghizistan 1
KW - Kuwait 1
KZ - Kazakistan 1
LB - Libano 1
LU - Lussemburgo 1
MK - Macedonia 1
MM - Myanmar 1
NG - Nigeria 1
PS - Palestinian Territory 1
QA - Qatar 1
SV - El Salvador 1
TT - Trinidad e Tobago 1
Totale 6.788
Salva come PNG Salva come JPEG
Città #
Singapore 353
Dallas 295
Moscow 278
Hong Kong 221
Ashburn 177
San Jose 153
Hefei 103
Shanghai 103
Lauterbourg 88
Beijing 83
Ho Chi Minh City 82
Lawrence 72
Princeton 72
Munich 64
New York 50
Los Angeles 49
São Paulo 44
Milan 40
Hanoi 36
Boardman 34
Orem 31
Warsaw 19
Denver 18
Manchester 18
Helsinki 17
Dublin 16
Tokyo 16
Montreal 15
Chennai 14
Johannesburg 14
Rio de Janeiro 14
Turku 14
Amsterdam 13
Da Nang 13
Guangzhou 13
Rome 13
Ankara 12
London 12
Mexico City 11
Mumbai 11
Phoenix 11
Poplar 11
Brasília 10
Brooklyn 10
Chicago 10
Haiphong 10
Nuremberg 10
Stockholm 10
The Dalles 10
Frankfurt am Main 9
Houston 9
Seattle 9
Vienna 9
Baghdad 8
Barnet 8
Dronten 8
Tehran 8
Tianjin 8
Ribeirão Preto 7
Tashkent 7
Washington 7
Atlanta 6
Pune 6
Amman 5
Belo Horizonte 5
Bergamo 5
Campinas 5
City of London 5
Duque de Caxias 5
Medellín 5
Osasco 5
Porto Alegre 5
Querétaro 5
Quito 5
Shenzhen 5
Toronto 5
Zurich 5
Aracaju 4
Buenos Aires 4
Cesano Boscone 4
Changsha 4
Charlotte 4
Cotia 4
Curitiba 4
Goiânia 4
Guarulhos 4
Guayaquil 4
Hangzhou 4
Izmir 4
Jacksonville 4
Lappeenranta 4
Miami 4
Piscataway 4
Salvador 4
San Francisco 4
Santa Clara 4
Santa Fe 4
Secaucus 4
Araçatuba 3
Belford Roxo 3
Totale 3.062
Salva come PNG Salva come JPEG
Nome #
The impact of PM2.5, PM10 and NO2 on Covid-19 severity in a sample of patients with multiple sclerosis: A case-control study 340
Application of Deep-Learning to NMOSD and Seronegative Patients with Limited NMOSD Manifestations 172
Neural stem cell transplantation in patients with progressive multiple sclerosis: an open-label, phase 1 study 158
Assessing the role of innovative therapeutic paradigm on multiple sclerosis treatment response 112
Subclinical neurodegeneration in multiple sclerosis and neuromyelitis optica spectrum disorder revealed by optical coherence tomography 110
Allogeneic hematopoietic stem cell transplantation for neuromyelitis optica. 108
U-Fiber Leukoencephalopathy Due to a Novel Mutation in the TACO1 Gene 107
Allogeneic haematopoietic stem cell transplantation in refractory neuromyelitis optica spectrum disorders 101
Acute myeloid leukemia in Italian patients with multiple sclerosis treated with mitoxantrone 99
A multiparametric score for assessing the individual risk of severe Covid-19 among patients with Multiple Sclerosis 97
Basal vitamin D levels and disease activity in multiple sclerosis patients treated with fingolimod 96
Magnetic Resonance Imaging Evaluation of Perivascular Space Abnormalities in Neuromyelitis Optica 93
Autologous haematopoietic stem cell transplantation with thiotepa-cyclophosphamide conditioning in aggressive multiple sclerosis: clinical experience in eight patients 93
In vivo structural and functional assessment of optic nerve damage in neuromyelitis optica spectrum disorders and multiple sclerosis 91
A cross-sectional, multicentre study of the therapeutic management of multiple sclerosis relapses in Italy 90
Caesarean section and infant formula feeding are associated with an earlier age of onset of multiple sclerosis 90
the multiple sclerosis knowledge Questionnaire: a self administered instrument of recently diagnosed patients 87
Effectiveness and baseline factors associated to fingolimod response in a real-world study on multiple sclerosis patients 87
Cohort profile: a collaborative multicentre study of retinal optical coherence tomography in 539 patients with neuromyelitis optica spectrum disorders (CROCTINO) 85
A pilot trial of low-dose naltrexone in primary progressive multiple sclerosis 84
Dysregulation of MS risk genes and pathways at distinct stages of disease 83
Brain and cord imaging features in neuromyelitis optica spectrum disorders 81
Application of deep-learning to NMOSD and unclassified seronegative patients 78
Breastfeeding is not related to postpartum relapses in multiple sclerosis 77
Autologous haematopoietic stem cell transplantation in aggressive forms of neuromyelitis optica (NMO) and NMO spectrum disorders 75
Cross-modal plasticity among sensory networks in neuromyelitis optica spectrum disorders 74
Autologous Bone Marrow Transplantation for the Treatment of Multiple Sclerosis 73
Concurrence of NMOSD and ALS in a patient with hexanucleotide repeat expansions of C9orf72 73
Clinical and MRI predictors of response to interferon‐beta and glatiramer acetate in relapsing–remitting multiple sclerosis patients 72
Comparative effectiveness of dimethylfumarate and fingolimod in an Italian monocentric cohort of relapsing remitting multiple sclerosis patients 71
Critical role for prokineticin 2 in CNS autoimmunity 69
Pregnancy and fetal outcomes after interferon-β exposure in multiple sclerosis 66
Are Recurrent Myelitis a Prodromic Phase of Inflammatory Diseases or a Distinct Inflammatory Condition? 65
Use of brain MRI and gene expression atlases to reconstruct the pathophysiology of autoimmune neurological disorders: The proof-of-concept of NMOSD 64
Experience of an information aid for newly diagnosed multiple sclerosis patients: A qualitative study on the SIMS-Trial 64
Smart watch, smarter EDSS: Improving disability assessment in multiple sclerosis clinical practice 64
Mapping white matter damage distribution in neuromyelitis optica spectrum disorders with a multimodal MRI approach 63
Forceps minor damage and co-occurence of depression and fatigue in multiple sclerosis 62
Artificial Intelligence on Conventional Magnetic Resonance Images for the Diagnosis of Neuromyelitis Optica Spectrum Disorders 62
Disease-Modifying Therapies and Coronavirus Disease 2019 Severity in Multiple Sclerosis 61
Comparative study of mitoxantrone efficacy profile in patients with relapsing-remitting and secondary progressive multiple sclerosis. 61
THIOTEPA-CYCLOPHOSPHAMIDE HIGH-DOSE IMMUNOSUPPRESSIVE THERAPY WITH AUTOLOGOUS HEMATOPOIETIC STEM CELL TRANSPLANTATION IN AGGRESSIVE FORMS OF MULTIPLE SCLEROSIS: RESULTS IN 9 PATIENTS 61
Thiotepa-cyclophosphamide high-dose immunosuppressive therapy with autologous haematopoietic stem cell transplantation in aggressive forms of multiple sclerosis: results in 9 patients 61
Natalizumab treatment after autologous haematopoietic stem cell transplantation in patients with aggressive multiple sclerosis 60
Functional brain connectivity abnormalities and cognitive deficits in neuromyelitis optica spectrum disorder 60
Mapping regional grey and white matter atrophy in relapsing-remitting multiple sclerosis. 59
Efficacy and tolerability of natalizumab in relapsing-remitting multiple sclerosis patients: A post-marketing observational study 59
Brain and Spinal Cord Imaging Features in Neuromyelitis Optica Spectrum Disorders 59
Pregnancy decision-making in women with multiple sclerosis treated with natalizumab: II: Maternal risks. 58
Postpartum relapses increase the risk of disability progression in multiple sclerosis: the role of disease modifying drugs. 58
Optical coherence tomography and visual-evoked potentials: which is more sensitive in multiple sclerosis? 57
Development and validation of a patient self-assessed questionnaire on satisfaction with communication of the multiple sclerosis diagnosis 57
Prognostic value of serum neurofilaments in patients with clinically isolated syndromes 57
Mitoxantrone: benefits and risks in multiple sclerosis patients 56
Efficacy and safety of nabiximols (Sativex (R)) on multiple sclerosis spasticity in a real-life Italian monocentric study 56
MGAT5 and disease severity in progressive multiple sclerosis 56
Evolving concepts in the treatment of relapsing multiple sclerosis 56
Thyroid autoimmunity and dysfunction in multiple sclerosis patients during long-term treatment with interferon beta or glatiramer acetate: An Italian multicenter study 56
Oral fingolimod (FTY720) in multiple sclerosis: Two-year results of a phase II extension study 55
Pregnancy decision-making in women with multiple sclerosis treated with natalizumab: I: Fetal risks. 55
Phase II study of oral fingolimod (FTY720) in multiple sclerosis: 3-year results 55
Dynamic pattern of clinical and MRI findings in a tumefactive demyelinating lesion: a case report 54
Depressive symptoms correlate with disability and disease course in multiple sclerosis patients: An Italian multi-center study using the Beck Depression Inventory 54
Neuromyelitis optica spectrum disorders: Long-term safety and efficacy of rituximab in Caucasian patients 54
Evoked potentials scores: a useful tool in monitoring and predicting the course of multiple sclerosis? 53
Evoked Potential Abnormalities Predict Disability Progression at 5 Years in Patients with CIS 53
Necrotic-hemorrhagic myelitis: A rare malignant variant of parainfectious acute disseminated encephalomyelitis in childhood 53
Disclosing the diagnosis of multiple sclerosis: The Profile Project 53
Sars-CoV2 infection in pregnant women with multiple sclerosis 52
White Matter Myelin Alterations are Diffuse in Neuromyelitis Optica Spectrum Disorders and Prevail on Axonal Damage 52
Practice of yoga may cause damage of bothsciaticnerves: a case report 52
Neuromyelitis optica remission after allo-SCT: results in 2 patients and correlation with T- and B-cell biomarkers of tolerance 52
Regional gray matter atrophy is largely unrelated to white matter tissue loss in relapsing remitting multiple sclerosis. 51
Recurrence of disease activity after repeated Natalizumab withdrawals. 50
Oral corticosteroids for multiple sclerosis relapse 50
Functional network connectivity abnormalities in multiple sclerosis: Correlations with disability and cognitive impairment 50
Multiple sclerosis progression is not associated with birth timing in Italy 49
Neuromyelitis optica: Concepts in evolution 49
Identifying neuropathic pain in patients with multiple sclerosis: a cross-sectional multicenter study using highly specific criteria. 49
White matter myelin alterations are diffuse in Neuromyelitis Optica spectrum disorders and prevail on axonal damage 49
Signs and symptoms of COVID-19 in patients with multiple sclerosis 48
Implementation of the 'Sapere Migliora' information aid for newly diagnosed people with multiple sclerosis in routine clinical practice: a late-phase controlled trial. 48
Long-term management of natalizumab discontinuation in a large monocentric cohort of multiple sclerosis patients. 48
Evoked potential abnormalities predict disability progression at 5 years in patients with CIS 48
Stem Cell-Based Therapies, Remyelination, and Repair Promotion in the Treatment of Multiple Sclerosis 46
Differential diagnosis of optic neuritis in neuromyelites optica and multiple sclerosis: are VEPs useful? 46
Impact of MS genetic loci on familial aggregation, clinical phenotype, and disease prediction. 45
Golbal and Regional Hippocampal Volumes Are Preserved In Neuromyelitis Optica and Do not Seem to Be Related to Cognitive Impairment 44
Global and regional hippocampal volumes are preserved in neuromyelitis optica spectrum disorders and do not contribute to cognitive impairment 44
NMO spectrum disorder and optic neuritis: are VEPs useful? 44
Hippocampal-DMN disconnectivity in MS is related to WM lesions and depression 44
Spinal cord atrophy in neuromyelitis optica is spatially associated to spinal cord lesions and clinical disability 44
Hippocampal regional vulnerability to damage differs between MS and neuromyelitis optica 43
White matter myelin alterations are diffuse in Neuromyelitis Optica Spectrum Disorders and prevail on axonal damage 41
Hippocampal Regional Vulnerability to Damage Differs Between MS and Neuromyelitis Optica 40
Revealing structural and clinical heterogeneity in the spectrum of neuromyelitis optica with unsupervised machine learning 39
Revealing structural and clinical heterogeneity in the spectrum of neuromyelitis optica with unsupervised machine learning 39
Hippocampal Regional Vulnerability to Damage Differs Between MS and Neuromyelitis Optica 39
Spinal cord atrophy in neuromyelitis optica spectrum disorders is associated to spinal cord lesions and clinical disability 38
Global and regional hippocampal volumes are preserved in neuromyelitis optica spectrum disorders and do not seem to be related to cognitive impairment 37
Totale 6.753
Salva come PNG Salva come JPEG
Categoria #
all - tutte 37.289
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 37.289
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/20211 0 0 0 0 0 0 0 0 0 0 1 0
2021/202244 0 0 0 30 1 2 1 3 2 3 0 2
2022/2023504 182 129 55 2 5 60 19 15 19 6 9 3
2023/2024229 7 26 22 26 27 42 4 20 0 7 10 38
2024/20251.593 130 14 20 59 69 85 434 102 262 131 121 166
2025/20264.464 339 376 378 679 350 187 357 314 1.291 193 0 0
Totale 6.888